This says it all. FDA will go against the panel and approve the drug, maybe conditional approval or temporary approval until new data is available. As for share price tomorrow, it's anyone's guess but I doubt it will drop significantly. Any weakness will be a buying opportunity.
"Janet Woodcock, the Food and Drug Administration’s director of drug evaluation, told panelists reviewing a potential drug for Duchenne muscular dystrophy this morning that there is a clear danger to patients in not approving a drug that works.
In comments before the advisory committee to review a drug developed by Cambridge-based Sarepta Therapeutics (Nasdaq: SRPT), Woodcock’s comments will be seen as largely supportive of accelerated approval of the drug. She seemed to outline a rationale under which the drug could be given accelerated approval, despite much speculation on Wall Street to the contrary in the past three months. She told the panel and the audience of hundreds who packed into the room that just as there is a danger in approving a drug that does not work, “Often there is never consideration of another error — that of not approving a drug that works,” she said."